Compare ResMed Inc. (RMD) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Teladoc Health Inc — how do they compare? ResMed Inc. trades at $225.19 (market cap $32.61B), while Teladoc Health Inc trades at $6.64 (market cap $1.24B). The key difference: ResMed Inc. is far larger — about 26.3× Teladoc Health Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| RMD | TDOC | |
|---|---|---|
Market Cap | $32.61B | $1.24B |
Sector | Health | Health |
52-Week High | $293.73 | $9.72 |
52-Week Low | $182.82 | $4.47 |
Enterprise Value | $31.97B | $1.50B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
TDOC trades at $6.66, down 5.93% amid bearish technical signals and negative sentiment following a Q2 2026 revenue miss and lowered full-year guidance. The stock shows weak profitability with a net income margin of -7.13% but trades below book value with a P/B of 0.94. Recent news highlights multiple law firm investigations into potential securities violations, adding to investor concerns.
The outlook remains challenging with revenue pressures in the BetterHelp segment and ongoing losses, though cost controls in Integrated Care provide some support. Analyst consensus is mixed with a $8.88 price target but high hold ratings, indicating cautious optimism amid significant operational and legal risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
